[
  {
    "ts": null,
    "headline": "Hartford Growth Opportunities Fund Q1 2025 Commentary",
    "summary": "The Hartford Growth Opportunities Fund (I Share) underperformed the Russell 3000 Growth Index during the quarter. Read more here.",
    "url": "https://finnhub.io/api/news?id=b44bd256d23b79f849fd26897a02f4ddcc1e3a0037f6e7edba09e100f587ddc3",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746658320,
      "headline": "Hartford Growth Opportunities Fund Q1 2025 Commentary",
      "id": 134314054,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2054524126/image_2054524126.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "The Hartford Growth Opportunities Fund (I Share) underperformed the Russell 3000 Growth Index during the quarter. Read more here.",
      "url": "https://finnhub.io/api/news?id=b44bd256d23b79f849fd26897a02f4ddcc1e3a0037f6e7edba09e100f587ddc3"
    }
  },
  {
    "ts": null,
    "headline": "Hartford Core Equity Fund Q1 2025 Commentary",
    "summary": "Hartford Core Equity Fund Q1 2025 Commentary",
    "url": "https://finnhub.io/api/news?id=628123fd0ae5f166c3eccd6e90f406a5962ccb18fc51660b756316ae1e3278ac",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746638580,
      "headline": "Hartford Core Equity Fund Q1 2025 Commentary",
      "id": 134309743,
      "image": "",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=628123fd0ae5f166c3eccd6e90f406a5962ccb18fc51660b756316ae1e3278ac"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly and Company (LLY): A Bull Case Theory",
    "summary": "We came across a bullish thesis on Eli Lilly and Company (LLY) on Substack by Kontra. In this article, we will summarize the bulls’ thesis on LLY. Eli Lilly and Company (LLY)’s share was trading at $794.10 as of May 1st. LLY’s trailing and forward P/E were 64.61 and 35.34 respectively according to Yahoo Finance. Eli Lilly […]",
    "url": "https://finnhub.io/api/news?id=6ff25f582d40ab50c6875b6dae05d2516e5d9f2e83c290240715d778ff9b926d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746638247,
      "headline": "Eli Lilly and Company (LLY): A Bull Case Theory",
      "id": 134316662,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "We came across a bullish thesis on Eli Lilly and Company (LLY) on Substack by Kontra. In this article, we will summarize the bulls’ thesis on LLY. Eli Lilly and Company (LLY)’s share was trading at $794.10 as of May 1st. LLY’s trailing and forward P/E were 64.61 and 35.34 respectively according to Yahoo Finance. Eli Lilly […]",
      "url": "https://finnhub.io/api/news?id=6ff25f582d40ab50c6875b6dae05d2516e5d9f2e83c290240715d778ff9b926d"
    }
  },
  {
    "ts": null,
    "headline": "Why Novo Nordisk missed its sales estimates on weight-loss drug Wegovy: CEO",
    "summary": "Investors are worried Novo Nordisk's competition with Eli Lilly is heating up and that the first-to-market GLP-1 leader is losing ground.",
    "url": "https://finnhub.io/api/news?id=23a6e113969e3565f4292effd093360bebf762429295d1e06168754f7b7eb7ed",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746636198,
      "headline": "Why Novo Nordisk missed its sales estimates on weight-loss drug Wegovy: CEO",
      "id": 134316663,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Investors are worried Novo Nordisk's competition with Eli Lilly is heating up and that the first-to-market GLP-1 leader is losing ground.",
      "url": "https://finnhub.io/api/news?id=23a6e113969e3565f4292effd093360bebf762429295d1e06168754f7b7eb7ed"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk Q1 Earnings Match Estimates, Revenues Rise Y/Y, Stock Up",
    "summary": "NVO stock gains after reporting first-quarter 2025 results, mainly due to expectations of U.S. sales recovery of its popular obesity drug, Wegovy.",
    "url": "https://finnhub.io/api/news?id=9e8c293485f904414ab2d9b6242375de494a37be0b6e75ce4f4ee12d808e7f8f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746628140,
      "headline": "Novo Nordisk Q1 Earnings Match Estimates, Revenues Rise Y/Y, Stock Up",
      "id": 134316664,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "NVO stock gains after reporting first-quarter 2025 results, mainly due to expectations of U.S. sales recovery of its popular obesity drug, Wegovy.",
      "url": "https://finnhub.io/api/news?id=9e8c293485f904414ab2d9b6242375de494a37be0b6e75ce4f4ee12d808e7f8f"
    }
  },
  {
    "ts": null,
    "headline": "Jim Cramer Says Eli Lilly and Company (LLY) CEO David Ricks Is ‘Very Conservative’",
    "summary": "We recently published an article titled Jim Cramer Says AI Is Back & Discusses These 10 Stocks. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other stocks. In a recent appearance on CNBC’s Squawk on the Street, Jim Cramer commented on how market sentiment […]",
    "url": "https://finnhub.io/api/news?id=8fb0ea197539995f1bec1bca2445b0fb102c9a09d3a228e66938926998c83c57",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746627863,
      "headline": "Jim Cramer Says Eli Lilly and Company (LLY) CEO David Ricks Is ‘Very Conservative’",
      "id": 134316665,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "We recently published an article titled Jim Cramer Says AI Is Back & Discusses These 10 Stocks. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other stocks. In a recent appearance on CNBC’s Squawk on the Street, Jim Cramer commented on how market sentiment […]",
      "url": "https://finnhub.io/api/news?id=8fb0ea197539995f1bec1bca2445b0fb102c9a09d3a228e66938926998c83c57"
    }
  },
  {
    "ts": null,
    "headline": "US judge sides with FDA's removal of Lilly's weight loss drug from shortage list",
    "summary": "A U.S. federal judge has sided with aU.S. regulator's decision last year to take Eli Lilly’sblockbuster weight loss and diabetes drugs Zepbound and Mounjarooff a list of medicines in short...",
    "url": "https://finnhub.io/api/news?id=3766406d1e1b9d6bcb4d69fa2cd13e95027cf2707a48de9050c1d0c34a3aae70",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746626554,
      "headline": "US judge sides with FDA's removal of Lilly's weight loss drug from shortage list",
      "id": 134297528,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "A U.S. federal judge has sided with aU.S. regulator's decision last year to take Eli Lilly’sblockbuster weight loss and diabetes drugs Zepbound and Mounjarooff a list of medicines in short...",
      "url": "https://finnhub.io/api/news?id=3766406d1e1b9d6bcb4d69fa2cd13e95027cf2707a48de9050c1d0c34a3aae70"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk Stock Jumps After Earnings. Compounding Market’s Growth Took it By Surprise",
    "summary": "The Danish drugmaker now expects sales growth between 13% and 21%, down from a previous range of 16% to 24%.",
    "url": "https://finnhub.io/api/news?id=26fe980a424be119a562e05f32c7315403f40e266b37a991a3cc9e67eab7026c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746626160,
      "headline": "Novo Nordisk Stock Jumps After Earnings. Compounding Market’s Growth Took it By Surprise",
      "id": 134316666,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The Danish drugmaker now expects sales growth between 13% and 21%, down from a previous range of 16% to 24%.",
      "url": "https://finnhub.io/api/news?id=26fe980a424be119a562e05f32c7315403f40e266b37a991a3cc9e67eab7026c"
    }
  },
  {
    "ts": null,
    "headline": "Company News for May 7, 2025",
    "summary": "Companies in The News Are: LLY, NEM, TSLA, ABNB",
    "url": "https://finnhub.io/api/news?id=2bc468a78e4339e91b996aa5c14c38e57c70381a4a762d21faf3390f7a5f5207",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746624480,
      "headline": "Company News for May 7, 2025",
      "id": 134316667,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Companies in The News Are: LLY, NEM, TSLA, ABNB",
      "url": "https://finnhub.io/api/news?id=2bc468a78e4339e91b996aa5c14c38e57c70381a4a762d21faf3390f7a5f5207"
    }
  },
  {
    "ts": null,
    "headline": "Teva Will Hike Generic Drug Prices If Trump Imposes Tariffs, CEO Says",
    "summary": "Teva Will Hike Generic Drug Prices If Trump Imposes Tariffs, CEO Says",
    "url": "https://finnhub.io/api/news?id=3300ea1b14e5de464f7f7025982a1b6b89585b313771611cb7e34f534b5b0fcc",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746622860,
      "headline": "Teva Will Hike Generic Drug Prices If Trump Imposes Tariffs, CEO Says",
      "id": 134298143,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Teva Will Hike Generic Drug Prices If Trump Imposes Tariffs, CEO Says",
      "url": "https://finnhub.io/api/news?id=3300ea1b14e5de464f7f7025982a1b6b89585b313771611cb7e34f534b5b0fcc"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk Q1 Earnings Review: Forget Revenue Miss, Buy Semaglutide Hype",
    "summary": "Novo Nordisk A/S' Q1 earnings reveal strong growth in semaglutide-driven sales despite a slight revenue miss. Learn more about NVO stock here.",
    "url": "https://finnhub.io/api/news?id=fc7936ebb687ca7dac9570109822a1d05d1e4c78895c2afa4af9a06cdb55454d",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746617373,
      "headline": "Novo Nordisk Q1 Earnings Review: Forget Revenue Miss, Buy Semaglutide Hype",
      "id": 134296542,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2158305431/image_2158305431.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Novo Nordisk A/S' Q1 earnings reveal strong growth in semaglutide-driven sales despite a slight revenue miss. Learn more about NVO stock here.",
      "url": "https://finnhub.io/api/news?id=fc7936ebb687ca7dac9570109822a1d05d1e4c78895c2afa4af9a06cdb55454d"
    }
  },
  {
    "ts": null,
    "headline": "Hims & Hers: Short Squeeze Or Strong Fundamentals? (Rating Downgrade)",
    "summary": "Hims & Hers Health sees strong Q1 results and expanded EBITDA guidance, but high short interest drives May 6 rally. Click here to read why HIMS stock is a Hold.",
    "url": "https://finnhub.io/api/news?id=2148a1d2026e00fc6cff9e429f713ec1335f5a14d0a8b2941362f3d5b471c451",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746616716,
      "headline": "Hims & Hers: Short Squeeze Or Strong Fundamentals? (Rating Downgrade)",
      "id": 134296302,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2184397606/image_2184397606.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Hims & Hers Health sees strong Q1 results and expanded EBITDA guidance, but high short interest drives May 6 rally. Click here to read why HIMS stock is a Hold.",
      "url": "https://finnhub.io/api/news?id=2148a1d2026e00fc6cff9e429f713ec1335f5a14d0a8b2941362f3d5b471c451"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk beats on Q1 earnings, cuts 2025 outlook",
    "summary": "Novo Nordisk reported moderate earnings, cuts 2025 outlook",
    "url": "https://finnhub.io/api/news?id=082b976c54525a87e39e43fd0a205844a737824b3738c8e1d6052a93485536e2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746615011,
      "headline": "Novo Nordisk beats on Q1 earnings, cuts 2025 outlook",
      "id": 134293534,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Novo Nordisk reported moderate earnings, cuts 2025 outlook",
      "url": "https://finnhub.io/api/news?id=082b976c54525a87e39e43fd0a205844a737824b3738c8e1d6052a93485536e2"
    }
  },
  {
    "ts": null,
    "headline": "Trump Is Threatening Big Pharma With Tariffs. Tax Changes Might Work Better.",
    "summary": "Trump Is Threatening Big Pharma With Tariffs. Tax Changes Might Work Better.",
    "url": "https://finnhub.io/api/news?id=50f7935301024748997581196a409fcf9b9f65bafd3b62d33e873aa4655fc8da",
    "source": "DowJones",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746595800,
      "headline": "Trump Is Threatening Big Pharma With Tariffs. Tax Changes Might Work Better.",
      "id": 134298123,
      "image": "",
      "related": "LLY",
      "source": "DowJones",
      "summary": "Trump Is Threatening Big Pharma With Tariffs. Tax Changes Might Work Better.",
      "url": "https://finnhub.io/api/news?id=50f7935301024748997581196a409fcf9b9f65bafd3b62d33e873aa4655fc8da"
    }
  },
  {
    "ts": null,
    "headline": "Fidelity Select Health Care Portfolio Q1 2025 Commentary",
    "summary": "For Q1 2025, the Fidelity Select Health Care Portfolio returned -1.03%, underperforming the MSCI health care index. Click here to read the full commentary.",
    "url": "https://finnhub.io/api/news?id=6de8cddaa404b5ed7aba0e6986a76a56106ac275d4255bad0da9cb9c149ff259",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746593700,
      "headline": "Fidelity Select Health Care Portfolio Q1 2025 Commentary",
      "id": 134290307,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/91598774/image_91598774.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "For Q1 2025, the Fidelity Select Health Care Portfolio returned -1.03%, underperforming the MSCI health care index. Click here to read the full commentary. ",
      "url": "https://finnhub.io/api/news?id=6de8cddaa404b5ed7aba0e6986a76a56106ac275d4255bad0da9cb9c149ff259"
    }
  }
]